Article
Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.
Breast (Edinburgh, Scotland) - 1 Jun 2026
De Angelis Carmine, de Biase Dario, Gerratana Lorenzo, Arpino Grazia, Bianchini Giampaolo, Castellano Isabella, Curigliano Giuseppe, Del Mastro Lucia, Fabi Alessandra, Fusco Nicola, Gennari Alessandra, Guarneri Valentina, Zamagni Claudio, Zambelli Alberto, Malapelle Umberto, Puglisi Fabio
Abstract excerpt
BACKGROUND: Alterations in the PI3K/AKT/mTOR signaling pathway represent a mechanism of resistance to endocrine therapy in advanced HR+/HER2-breast cancer. The identification of activating mutations in PIK3CA has gained therapeutic relevance, guiding the use of PIK3CA-targeted inhibitors such as alpelisib and inavolisib. METHODS: A multidisciplinary panel of Italian experts conducted a structured consensus...
Topics
- Female
- Humans
- Breast Neoplasms
- Class I Phosphatidylinositol 3-Kinases
- Erb-b2 Receptor Tyrosine Kinases
- Italy
- Mutation
- Receptors, Estrogen
- Receptors, Progesterone